Failure of alemtuzumab therapy to control MOG encephalomyelitis

Neurology. 2017 Jul 11;89(2):207-209. doi: 10.1212/WNL.0000000000004087. Epub 2017 Jun 9.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alemtuzumab / therapeutic use*
  • Diagnostic Errors*
  • Encephalomyelitis / complications
  • Encephalomyelitis / drug therapy*
  • Encephalomyelitis / immunology
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Multiple Sclerosis / complications
  • Multiple Sclerosis / diagnosis*
  • Multiple Sclerosis / drug therapy*
  • Myelin-Oligodendrocyte Glycoprotein / immunology*
  • Treatment Failure

Substances

  • Immunosuppressive Agents
  • Myelin-Oligodendrocyte Glycoprotein
  • Alemtuzumab